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Abstract 28 
Background – Flow cytometry (FC) is used increasingly in veterinary medicine for further 29 
characterization of hematolymphoid cells. Guidelines for optimizing assay performance and 30 
interpretation of results are limited, and concordance of results across laboratories is unknown.  31 
Objectives – To determine inter-investigator agreement on interpretation of FC results from split 32 
samples analyzed in different laboratories using various protocols, cytometers and software; and 33 
on interpretation of archived FC standard (FCS) data files contributed by different investigators.  34 
Methods – Multicenter observational cross-sectional study. Anticoagulated blood or lymph node 35 
aspirate samples from 9 client-owned dogs were aliquoted and shipped to participating 36 
laboratories. Samples were analyzed with individual laboratory-developed protocols. In addition, 37 
FCS files from a set of separate samples from 11 client-owned dogs were analyzed by 38 
participating investigators. A study non-participant tabulated results and interpretations. 39 
Agreement of interpretations was assessed with Fleiss’ kappa statistic.  40 
Results – Prolonged transit times affected sample quality for some laboratories. Overall 41 
agreement among investigators regarding FC sample interpretation was strong (κ = .86±.19, P < 42 
.001), and for specific categories ranged from moderate to perfect. Agreement on category of 43 
lymphoproliferation or other leukocyte sample from analysis of FCS files was weak (κ = 44 
.58±.05, P < .001).  45 
Conclusions – Lymphoproliferations were readily identified by FC but identification of 46 
categories of hematolymphoid neoplasia in fresh samples or archived files was variable. There is 47 
a need for a more standardized approach to maximize the enormous potential of FC in veterinary 48 
medicine.  49 
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Introduction  52 
Flow cytometry (FC) is a laser-based analytic technique whereby multiple concurrent light 53 
scatter and light emitting properties of cells are measured.1 Assessment of hematolymphoid 54 
neoplasms in humans typically incorporates flow cytometric immunophenotyping of leukocytes 55 
with panels of fluorochrome-labeled antibodies, in addition to morphologic, cytogenetic and 56 
molecular evaluation.2 In animals, FC is a commonly used research tool, but clinical applications 57 
for characterization of hematolymphoid neoplasms have only evolved in recent years.1,3,4 58 
Cytogenetic and molecular assays other than analysis of clonality of antigen receptor genes are 59 
rarely used for diagnostic purposes. Flow cytometry is a complex analytic technique with many 60 
potential variables introduced by sample collection, preparation, analysis, and interpretation, 61 
which can profoundly affect results.1,5 Furthermore, most instruments used in veterinary 62 
medicine are not validated for diagnostic purposes, and voluntary or mandatory quality assurance 63 
(QA) or quality control (QC) programs are uncommon. However, with increasing knowledge 64 
regarding the prognosis of different immunophenotypes of hematolymphoid neoplasms in 65 
animals,3,4,6-10 results of FC have the potential to profoundly impact patient management. 66 
 In human medicine, consensus documents to guide all analytical aspects of clinical FC 67 
have been in place for several decades, and instruments and reagents are designated specifically 68 
for clinical use with limited adjustability and variability.11-16 Furthermore, clinical laboratories 69 
for human samples are subject to national or regional QA/QC programs.17,18 Laboratories abide 70 
by such guidelines to fulfill legal and accreditation requirements, and to provide optimal patient 71 
care.11-13,15-17,19-22 Proficiency testing (PT) is one component of QA. In the United States, a 72 
common PT program administered by the College of American Pathologists (CAP) consists of 2 73 
to 3 shipments of 2 to 3 samples (blood, bone marrow or organ aspirates) per year sent to 74 
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participating laboratories for analysis and comparison of results.18 Samples in individual 75 
laboratories are analyzed by FC in the same manner as other patient specimens, and results are 76 
reported back to the CAP. Deviation from expected results requires correction of assay 77 
performance to ensure accurate patient results and to meet requirements for laboratory 78 
accreditation.  79 
 Neither consensus recommendations nor quality programs for veterinary clinical FC 80 
analysis have been established. For that reason, a FC interest group was formed at the joint 81 
annual meeting of the American College of Veterinary Pathologists (ACVP) and the American 82 
Society for Veterinary Clinical Pathology (ASVCP) in Atlanta, Georgia, in 2014. The group has 83 
subsequently met annually, and includes representatives from academic and commercial 84 
laboratories from North America and Europe performing or planning to establish diagnostic 85 
veterinary FC. As a first step towards establishing consensus recommendations, a PT program 86 
was initiated to compare immunophenotyping results between laboratories. Results of the PT 87 
initiative, and recommendations for minimum standards in veterinary FC, are presented here.  88 
 89 
Material and Methods 90 
Patient samples  91 
Samples for FC were obtained between February 1, 2015 and July 31, 2017. All samples were of 92 
canine origin and had been submitted for diagnostic testing for suspected hematopoietic 93 
neoplasia to Cornell, North Carolina State, Georgia or Guelph University. Samples for PT were 94 
left over after diagnostic testing; therefore, ethics committee approval was not obtained but 95 
owners provided written consent for testing. Lymph node (LN) aspirates were placed into FC 96 
buffer (1x phosphate-buffered saline supplemented with 1% heat-inactivated fetal bovine serum, 97 
1% 0.5 M potassium EDTA [K-EDTA], and 1% sodium azide), and peripheral blood (PB) 98 
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samples were placed into K-EDTA tubes. Samples were aliquoted and shipped by courier on ice 99 
overnight Monday through Wednesday within 24 hours after sample acquisition. Patient 100 
signalment and numerical CBC results were provided, but neither cytologic, histopathologic, nor 101 
additional clinical findings were provided before the FC analysis was completed.  102 
 103 
Analysis of fresh samples by FC 104 
Samples were selected for inclusion according to availability of adequate specimen volume, and 105 
ability to be shipped and analyzed during regular working hours. Immunophenotyping was 106 
performed using individual laboratory developed test (LDT) protocols, as previously reported by 107 
several laboratories.6,7,10,23,24 In general, samples were aliquoted into FC polypropylene tubes. 108 
Red blood cells were lysed according to individual LDT protocols, which included ammonium-109 
chloride-potassium (ACK) buffer or water lysis of blood, bone marrow and LN specimens. Then, 110 
antibodies were added as per LDT protocol (Table 1). Samples were analyzed using laboratory-111 
specific FC instruments. Specimens with insufficient cells or poor viability (<50%) were 112 
excluded from analysis. Viability assessment was according to individual LDT protocols and 113 
included Trypan blue staining before FC cell preparation and/or incorporating a viability dye 114 
such as 7-aminoactinomycin D (7-AAD) or propidium iodide (PI) into the FC staining protocol.  115 
 116 
Analysis of archived FC files 117 
Participants also analyzed a set of archived FC standard (FCS) data files from dogs with 118 
hematopoietic neoplasia (hereafter referred to as ‘files’) distinct from those submitted as fresh 119 
samples (‘samples’). The files were generated with instrument-specific acquisition software by 120 
each laboratory using LDT protocols and saved in generic FCS 3.0 format for opening with 121 
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different analytic software. Each file was provided with information on the combination of 122 
antibodies and fluorochromes, event number, nature of control samples, and the instrument used 123 
for acquisition.  124 
 125 
Reporting of results 126 
For fresh samples, each participant generated a written report including the percentage of viable 127 
cells, percentage of cells in the various leukocyte subsets as defined by a common set of 128 
antibodies (Table 2), and interpretations as routinely generated by each participant. An individual 129 
who did not participate in data acquisition or analysis compiled all results into a spreadsheet. 130 
Individual laboratory names were not recorded but rather a number was randomly assigned to 131 
each laboratory for each sample to allow blinded interpretation of results.  132 
Results of fresh samples were grouped into the following categories: ‘CD4+ T cell 133 
lymphoproliferation’ (expanded population of CD4+/CD3+ or CD4+/CD5+ cells), ‘CD8+ T cell 134 
lymphoproliferation’ (expanded population of CD8+/CD3+ or CD8+/CD5+ cells), ‘CD4-CD8- T 135 
cell lymphoproliferation’ (expanded population of CD3+/CD4-/CD8- and/or CD5+/CD4-/CD8- 136 
cells) or ‘B cell lymphoproliferation’ (expanded population of CD21+ cells). An expanded cell 137 
population with particular light scatter and immunophenotypic features was defined by 138 
individual LDT protocols. Other categories were ‘mixed’ (mixed population of cells with 139 
variable immunophenotypes inconsistent with neoplasia and therefore supportive of a reactive 140 
process) and ‘other’ (samples for which the constellation of antigen detection was equivocal for 141 
a neoplastic or reactive process, or samples that did not meet criteria of the above categories). 142 
Finding a predominance of cells with an aberrant immunophenotype, such as lack of antigens 143 
usually expressed on leukocytes, or an atypical constellation of antigens, was also considered 144 
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supportive of neoplasia. Percentage of cells positive for an antigen was determined from 145 
investigator-set gates, which in turn was based on forward-light scatter (FSC) and side-light 146 
scatter (SCC) characteristics of cells and/or detection of a common leukocyte antigen.  147 
Archived files were interpreted in a similar manner as described above. Each investigator 148 
was provided with a set of FCS files for interpretation. A category of ‘CD4+CD8+ T cell 149 
lymphoproliferation’ was added for samples with an expanded population of CD4+/CD8+/CD3+ 150 
or CD4+/CD8+/CD5+ cells. ‘Other’ could be an interpretation of ‘equivocal’ regarding neoplastic 151 
or reactive immunophenotype, or samples that did not meet criteria of the other categories.  152 
 153 
Statistical analysis 154 
Agreement among participants was assessed using Fleiss’ kappa analysis in MS Excel 2013.25 155 
Agreement was determined for overall sample and file interpretations, and for identification of 156 
individual categories. Graphs were generated with GraphPad Prism (version 7). For Fleiss’ kappa 157 
statistics, each sample needs to be evaluated by an equal (fixed) number of raters. Raters do not 158 
necessarily have to be the same for each sample. To meet this requirement, the number of raters 159 
(n = x) was restricted to the minimum number of participating investigators for each sample, 160 
meaning that each sample had to be evaluated at least x times. Therefore, cases with more than n 161 
= x raters (n = x + y), n = y raters were randomly excluded from the analysis using the Excel 162 
randomization function. For example, if overall the minimum number of investigators per sample 163 
was 7, each sample had to be evaluated at least 7 times, therefore, if a sample was analyzed by 8 164 
investigators, one investigator had to be randomly excluded from the statistical analysis. 165 
Agreement was defined as ‘no agreement’ for κ = -.10 – .2; ‘minimal agreement’ for κ = .21 – 166 
.39; ‘weak agreement’ for κ = .4 – .59; ‘moderate agreement’ for κ = .6 – .79; ‘strong 167 
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agreement’ for κ = .8 – .9; ‘almost perfect agreement’ for κ = .91 – .99, and ‘perfect agreement’ 168 
κ = 1.0.26 Kappa values with standard errors were calculated, and P ≤ .05 was considered 169 
statistically significant.  170 
 171 
Results  172 
Source of fresh FC samples 173 
Nine fresh samples were analyzed, and 9 laboratories participated in the analysis of the fresh 174 
samples (Table 3). Not all laboratories received samples suitable for analysis or were able to 175 
analyze samples at particular time points; therefore, between 4 and 9 results were available for 176 
any particular fresh sample. Samples consisted of peripheral blood (PB) from 7 dogs, labeled as 177 
sample numbers: 1 – female spayed (FS) German shorthaired Pointer, 0.9 years, marked 178 
leukocytosis and systemic blastomycosis; 4 – FS mixed breed dog, 11 years, lymphocytosis; 5 – 179 
FS mixed breed dog, 10 years, no clinical abnormalities; 6 – FS mixed breed dog, 11 years, 180 
cytologically unclassifiable leukocytes; 7 – FS Golden retriever, 11 years, lymphocytosis; 8 – 181 
male neutered (MN) Golden retriever, 12 years, pancytopenia and unclassifiable leukocytes; 9 – 182 
FS Doberman Pinscher, 12 years, lymphocytosis and cytological diagnosis of lymphoid 183 
neoplasia. Two LN aspirates were derived from dogs with a cytological diagnosis of lymphoma: 184 
2 – FS Weimaraner, 5 years; 3 – MN German Shepherd mixed breed dog, 3 years.  185 
 186 
Pre-analytical aspects 187 
Pre-analytical factors precluded sample assessment in some cases (Figure 1). For example, 188 
sample 1 (PB) could not be analyzed due to a transit delay of >72 hours resulting in hemolysis 189 
and poor (<50%) cell viability or tube breakage (3 and 5 laboratories, respectively). Sample 2 190 
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arrived with insufficient or poorly viable cells (<5%) in 2 and 1 laboratories, respectively. 191 
Sample 3 was not interpreted by 2 investigators because of poor cell viability (15% and <5%, 192 
respectively). No pre-analytical problems were encountered for the remaining 6 samples. 193 
Cytometers used were Accuri C6, LSR II, FACSCalibur, FACSCanto II, LSR Fortessa X-20 (all 194 
BD Biosciences, San Jose, CA) in 1, 3, 2, 1 and 1 laboratory, respectively, and Gallios (Beckman 195 
Coulter, Brea, CA) in 1 laboratory. 196 
 197 
Interpretation of fresh samples 198 
At least four interpretations per sample were available. The overall agreement between all 199 
participating investigators regarding the immunophenotype of the 9 fresh samples was strong (κ 200 
= 0.86 ± 0.19; P < .001, Table 3 and Figure 1). Agreement was moderate for ‘CD4+ T cell 201 
lymphoproliferation’ (κ = .64 ± .41; P = .119), perfect for ‘CD8+ T cell lymphoproliferation’ (κ = 202 
1 ± .41; P < .014), perfect for ‘CD4-CD8- T cell lymphoproliferation’ (κ = 1 ± .41; P < .014), 203 
moderate for ‘B cell lymphoproliferation’ (κ = .75 ± .20; P < .001), perfect for ‘mixed’ 204 
immunophenotype (κ = 1 ± .29; P < .001) and moderate for ‘other’ (κ = .77 ± .29; P = .008). 205 
Within the ‘other’ category, sample 2 was interpreted as inconclusive by one investigator but as 206 
a B cell lymphoproliferation by the other 3; sample 8 was interpreted as an undifferentiated 207 
leukemia by all investigators due to absence of antigen detection and abnormal cells in 208 
circulation.  209 
 210 
Source of archived FCS files 211 
Eight laboratories provided 11 archived FCS files for analysis (Table 4); 3 laboratories provided 212 
2 cases each and 5 laboratories provided 1 case each. FCS files were generated from PB of 3 213 
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dogs: File 1 - FS mixed breed dog, 13 years; file 6 – MN Shih Tzu, 10 years; file 7 – FS mixed 214 
breed dog, 12 years. LN aspirates were from 6 dogs: File 2 – MN Golden retriever, 9 years; file 3 215 
– FS Cavalier King Charles spaniel, 4 years; file 4 – FS Dogue de Bordeaux, 7 years; file 5 – FS 216 
German Shepherd, 12 years; file 8 – MN Boxer, 6 years; file 11 – FS mixed-breed, adult. 217 
Additional samples originated from an aspirate of a mediastinal mass in a FS Blue Heeler, 8 218 
years (file 9), and PB, LN, and bone marrow from a male Jack Russell terrier, 9 years (file 10). 219 
All dogs had a cytologic diagnosis of lymphoid neoplasia.  220 
 221 
Interpretation of archived FCS files 222 
FlowJo, FACSDiva and Cell Quest (all BD Biosciences) software was used by 4, 2 and 1 223 
investigator, respectively, and Kaluza (Beckman Coulter) was used by 1 investigator for 224 
analysis. Software used by some investigators was unsuitable for the FCS format generated by 225 
acquisition software of some cytometers, i.e. files 1, 2, and 4 were not analyzable by three, four 226 
and five of eight investigators, respectively (‘uninterpretable’; Table 4, Figure 2). Files that were 227 
categorized into ‘other’ included file 4 (interpreted as presumptive unclassified leukemia), file 7 228 
(interpreted as equivocal for a neoplastic or reactive process), file 8 (interpreted equivocal as B 229 
or T cell neoplasm), and file 9 (interpreted as thymoma) by one investigator each. Overall 230 
agreement between investigators was weak (κ = .58 ± 0.05, P < .001). For individual categories, 231 
agreement was strong for ‘B cell lymphoproliferation’ (κ = .85 ± 0.11; P < .001), moderate for 232 
‘CD4+’ (κ = .76 ± 0.08; P < .001) and ‘CD8+’ (κ = .76 ± .11; P < .001) ‘T cell 233 
lymphoproliferation’, minimal for ‘CD4+CD8+’ T cell lymphoproliferation’ (κ = .29 ± .09; P = 234 
.002) and ‘uninterpretable’ (κ = .37 ± .11; P < .001), with no agreement for the diagnosis of 235 
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‘CD4-CD8-T cell lymphoproliferation’ (κ = .03 ± .09; P = .77) and ‘other’ (κ = -.05 ± .08; P = 236 
.54) (Table 4, Figure 2). No files were interpreted as ‘mixed’ or reactive.   237 
 238 
Discussion  239 
In human medicine, FC immunophenotyping is a standardized clinical test using cytometers with 240 
limited adjustability and automatic gating algorithms subject to proficiency assessment.27 In 241 
animals, FC has been applied as a research tool for decades but use as a diagnostic test is in the 242 
very early stages. At this point, there are no consistent protocols for cell preparation, antibody 243 
type, antibody amount, use of controls, data analysis or interpretation. For example, cell 244 
preparation can vary substantially between laboratories, ranging from samples prepared in tubes 245 
or 96-well plates, single-fluorochromes applied in two-step format or 2 to 8 directly conjugated 246 
antibodies applied concurrently. A unified format for reporting of FC results by the European 247 
canine lymphoma network has been proposed but a similar recommendation for pre-analytical or 248 
analytical FC aspects remains to be constructed.28 If primary and secondary antibodies are used, 249 
both need to be titrated using appropriate target cells, and multiple concurrent antibodies need to 250 
be tested in combination for fluorochrome interference and spectral overlap. Concerning human 251 
clinical samples, many approaches have been described for this purpose, and discussions are 252 
ongoing regarding improved preparatory and analytical methods.29,30 Various cytometers are 253 
used in veterinary diagnostic laboratories and they are often designed for adjustability to serve 254 
multiple cell types and species in research rather than for clinical purposes. Different cytometers 255 
also have variable acquisition software. Other challenges toward establishing FC as a 256 
standardized test in veterinary laboratory medicine are limited availability of validated antibodies 257 
directed to animal leukocyte antigens, and lack of reactivity of most of such antibodies with 258 
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antigens that have been formalin exposed. Hence, only fresh samples can be analyzed but that 259 
poses challenges with timely shipment. Finally, there are idiosyncrasies of animal leukocytes 260 
such as expression of CD4 on canine neutrophils and loss of CD45 on T zone lymphoma cells, 261 
which require specific expertise for interpretation.31,32 This study was a first voluntary effort 262 
involving institutions that perform diagnostic veterinary FC for the purpose of 1) describing 263 
reagents and instruments being used; 2) assessing concordance of results from analysis of split 264 
samples; and 3) assessing concordance of interpretation of archived FCS files.  265 
 266 
Nine laboratories participated in analysis of fresh samples, but not all received suitable samples 267 
in a timely manner nor was sufficient sample available for all participating laboratories. Since 268 
fresh samples needed to be shipped across long distance and borders, cell viability was poor in 269 
several instances. Samples with viability <50% were excluded, but reduced cell integrity might 270 
still have contributed to non-specific antibody binding and therefore discrepant interpretations. 271 
Agreement between investigators on identification of lymphoproliferation was strong, but 272 
agreement on categories such as CD4+ T cell and B cell tumors was moderate. Moderate 273 
agreement constitutes a quality problem for clinical laboratory tests in human medicine and is 274 
considered inadequate in healthcare research.26 Moderate agreement would also be of concern 275 
for immunophenotyping canine lymphoid neoplasms. Response to therapy and survival vary 276 
among dogs with different T cell tumors, and also among dogs with B or T cell tumors.6,7,10 277 
Reliable identification of T versus B cell predominance is essential for basic 278 
immunophenotyping, and lack thereof precludes more detailed assessment of subcategories. 279 
Discrepancies in sample interpretation such as sample 3 being considered ‘CD4+ T cell 280 
lymphoma’ by three investigators, and ‘B cell lymphoma’ by a fourth investigator, might arise 281 
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from unfamiliarity with the constellation of antibodies being used, inappropriate instrument set-282 
up, inappropriate fluorochrome compensation, lack of assessment of a corresponding blood or 283 
lymph node aspirate smear, differing gating strategies or limited experience with a highly 284 
complex analytic technique such as FC. Similar reasons might account for sample 2 being 285 
interpreted as ‘B cell lymphoma’ by three investigators, and as ‘equivocal’ by a fourth 286 
investigator. Such variability in interpretation might in part be addressed through consensus on 287 
use of reagents, methods and analytic approaches, and increased training. Achieving uniformity 288 
in cytometer use is cost-prohibitive and therefore unrealistic at this time.  289 
 290 
In principle, analysis of archived FCS files should generate concordant results regardless of the 291 
type of analytical software used. However, variable agreement was observed, which is also of 292 
concern due to the potential impact on patient management. Disparate interpretations may reflect 293 
differences in gating strategies, experience with certain antibody-fluorochrome combinations, 294 
types of controls used, compensation approaches, and types of instruments and analytical 295 
software. For example, FCS files generated by some instruments have pre-set scales for light 296 
scatter and fluorescence, which require manual adjustment with some other analytic software to 297 
visualize all cell populations. Variable computational software contributing to differences in 298 
interpretation were also reported for analysis of human FC samples.33 The recently introduced 299 
open source software CytoML, an R/Bioconductor package, is reported to facilitate cross-300 
platform import, export and analysis of cytometry data, and may be useful for future studies in 301 
veterinary FC.34 302 
   303 
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There are several limitations of this study. Samples did not have a gold standard diagnosis but 304 
rather all results were considered independent and the goal was not to compare results of 305 
different investigators relative those of submitting investigator, but rather to assess overall 306 
agreement. A gold standard would not be easy to generate since most antibodies reactive with 307 
formalin-fixed tissues are different than those used for FC. Nevertheless, establishment of a gold 308 
standard diagnosis from a combination of morphologic combined with immunohistochemical or 309 
immunocytochemical assessment of concurrent patient samples, or Bayesian statistics taking all 310 
pertinent clinical and diagnostic information into account, should be considered in future studies. 311 
The majority of samples were PB, since obtaining sufficiently cellular samples for 9 laboratories 312 
was rarely feasible from LN aspirates. Leukocytes are better preserved in blood than in FC buffer 313 
used for LN or organ aspirates; therefore, PB is more suitable for possible time-delayed analysis. 314 
Sample tubes containing proprietary preservative have been tested for prolonging the analytical 315 
lifespan of canine lymphocytes, but decreased immunoreactivity and viability occurred after 3 316 
days.35 Thus, future studies will likely still have to rely on fresh samples. 317 
Results of this study do not invalidate previous findings using FC as a diagnostic assay for 318 
immunophenotyping canine lymphoproliferative diseases. Concordance between FC and IHC for 319 
immunophenotyping canine T and B cell lymphomas was previously reported to be high 320 
(Thalheim 2013), and entities such as T zone lymphoma were reproducibly identified using FC 321 
by multiple investigators (6, 10). However, findings in the present study indicate need for 322 
improved concordance in the analysis of canine FC samples. This will require development of 323 
consensus standards for all analytical aspects of clinical FC. It would be highly desirable to 324 
arrive at a peer-reviewed Optimized Multicolor Immunofluorescence Panel (OMIP) for 325 
veterinary FC, as established for human leukocytes in general and for specific leukocyte 326 
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subpopulations.36,37 A sample canine multicolor panel with a rationale is provided in Appendix 1 327 
(Supplementary File). In the interim, FC should be recognized as a very powerful technique to be 328 
used in conjunction with morphologic cell and tissue assessment, clonality and 329 
immunohistochemical assays. 330 
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Table 1. Antigens detected and antibodies used routinely for flow cytometric characterization of 450 
dog leukocytes by different laboratories.  451 
  Laboratorya 
Antigen Clone Target species 1 2 3 4 5 6 7 8 9 10 
CD1ab CA9.AG5 Canine    X        
CD1a CA13.9H11 Canine    X        
CD3 CA17.2A12 Canine  X X X X X X X X X X 
CD3 CD3-12 Human       X   X  
CD4 CA13.1E4 Canine    X        
CD4 YKIX302.9 Canine  X X  X X X X X X X 
CD5 YKIX322.3 Canine  X X X X X X X X X X 
CD8α CA9.JD3 Canine    X        
CD8α YCAT 55.9 Canine  X X  X X X X X X X 
CD8β CA15.4G2 Canine    X        
CD11/18 YKIX490.6.4 Canine     X    X X  
CD11a CA11.4D3 Canine    X        
CD11a HI111 Human          X  
CD11b CA16.3E10 Canine  X  X        
CD11c CA11.6A1 Canine  X  X        
CD11d CA16.3D3 Canine    X        
CD11d CA11.8H2 Canine  X  X        
CD14 TUK4 Human  X X X X  X X   X 
CD18 CA1.4E9 Canine  X  X X       
CD18 YFC118.3 Human   X        X 
CD21 CA2.1D6 Canine   X X X  X  X X X 
CD21 B-ly4 Human  X    X  X    
CD22 RFB4 Human  X X  X       
CD25 P4A10 Canine  X X        X 
CD34 1H6 Canine X X X X X X X X X X 
CD45 CA12.10C12 Canine    X        
CD45 YKIX716.13 Canine  X X  X X X X X X X 
CD45RA CA4.1D3 Canine    X      X  
CD49d CA4.5B3 Canine   X        
CD79a HM57 Human         X X  
CD79b AT107-2 Murine       X     
CD90 CA1.4G8 Canine  X  X X       
CD90 YKIX337.217 Canine            
MHC IIc CA2.1C12 Canine    X X X      
MHC II YKIX334.2 Canine  X X     X X X X 
TCR α/βd CA15.8G7 Canine  X  X        
TCR γ/δ CA20.6A3 Canine    X        
B5 Clone B5 Canine       X     
a 1, Cornell University; 2, Colorado State University; 3, University of California Davis; 4, University of Guelph; 5, 452 
Kansas State University; 6, North Carolina State University; 7, The Ohio State University; 8, University of Milan; 9, 453 
University of Vienna; 10, University of Georgia 454 
b Allele-specific reactivity 455 
c Major histocompatibility complex 456 
d TCR, T-cell receptor 457 
458 
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Table 2. Antigens detected in this study.   459 
  460 
Antigen  Normal cell expression   
CD3a T-lymphocytes 
CD4 Helper T-lymphocytes; neutrophils 
CD5 Most T-lymphocytes 
CD8 Cytotoxic T-lymphocytes 
CD21 B-lymphocytes 
CD45 Leukocytes  
MHC IIb Lymphocytes, monocytes, macrophages, dendritic cells 
a CD, Cluster of differentiation 461 
b MHC, major histocompatibility complex 462 
463 
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Table 3 – Categorization of fresh blood (PB) and lymph node (LN) samples from dogs by flow 464 
cytometric analysis. Nine investigators participated, and a minimum of 4 investigators 465 
interpreted each sample. Overall agreement between investigators regarding the type of 466 
hematolymphoid proliferation was strong (κ = .86 ± .19; P <.001).  467 
 468 
   Type of proliferation   
Sample  Source   T cell   B cell d  
 
 
 
   CD4+ a CD8+ b CD4-CD8- c   Mixed e Other f 
1  PB  - - - 
 
- 4 - 
2  LN  - - - 
 
3 - 1 
3 LN  3 - - 
 
1 - - 
4  PB  - - - 
 
4 - - 
5  PB  - - -  - 4 - 
6  PB  - 4 -  - - - 
7 PB  - - 4  - - - 
8 PB  - - - 
 
- - 4 
9  PB  - - - 
 
4 - - 
κ   .64 1 1 
 
.75 1 .77 
SE   .41 .41 .41  .20 .29 .29 
P   .119 .014 .014  <.001 < .001 .008 
95% CI   -.16-1.43 .19-1.80 .19-1.80  .35-1.15 .43-1.15 .20-1.33 
CD, cluster of differentiation; CI, confidence interval; κ, kappa; SE, standard error 469 
a Expanded population of CD4+/CD3+ or CD4+/CD5+ cells  470 
b Expanded population of CD8+/CD3+ or CD8+/CD5+ cells  471 
c Expanded population of CD4-/CD8-/CD3+ or CD4-/CD8-/CD5+ cells 472 
d Expanded population of CD21+ cells 473 
e Population of cells with variable immunophenotypes inconsistent with neoplasia 474 
f Constellation of antigen expression equivocal for a neoplastic or reactive process 475 
  476 
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Table 4 – Categorization of flow cytometry standard (FCS) files from blood (PB), lymph node (LN) and other tissue aspirate samples 477 
by 8 different investigators. Overall agreement regarding the type of proliferation of hematolymphoid cells was weak (κ = .58 ± .05; P 478 
<.001). The category ‘uninterpretable’ includes files that investigators could not analyze due to software incompatibilities.  479 
   Type of proliferation    
File Source 
 T cell  B cell  
Mixed 
 
Other 
 
Uninterpretable  CD4+ CD8+ CD4+CD8+ a CD4-CD8-   
1 PB  - - 5 -  - - - 3 
2 LN  1 - 1 1  1 - - 4 
3 LN  - 1 - -  7 -   
4 LN  - - - 2  - - 1 5 
5 LN  - - 1 -  8 -   
6 PB  7 - - -  - -   
7 PB  - 7 - -  - - 1  
8 LN  7 - - -  - - 1  
9 Massb  6 - 1 -  - - 1  
10 Multiplec  - 7 - 1  - -   
11 LN  8 - - -  - -   
κ   .76 .76 .29 .03  .85 n/a -.05 .37 
SE   .08 .11 .09 .09  .11 n/a .08 .11 
P   < .001 < .001  .002 .77  < .001 n/a .54 < .001 
95% CI  .59-.93 .55-.97 .11-.48 -.16-.21  .63-1.06 n/a -.20-.10 .15-.58 
 480 
a Expanded population of CD4+/CD8+/CD3+ or CD4+/CD8+/CD5+ cells.  481 
b Mediastinal mass  482 
c Blood, lymph node, and bone marrow 483 
For other abbreviations, see legend Table 3   484 
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Figure Captions 485 
Figure 1. Graph plot depicting flow cytometric interpretation of individual freshly analyzed 486 
samples separated by sample type and immunophenotypic category. Samples of poor quality are 487 
shown as ‘uninterpretable’ and were excluded from analysis. At least 4 investigators interpreted 488 
each sample, hence agreement was determined by random exclusion of any number of 489 
interpretations greater than four (see Table 3). Cells in sample 8 lacked expression of 490 
differentiating antigens and this sample was interpreted as undifferentiated leukemia (‘other’). 491 
Mixed: Populations of cells with variable immunophenotypes inconsistent with neoplasia. Other: 492 
Constellation of antigen expression equivocal for a neoplastic or reactive process. 493 
Uninterpretable: Samples with insufficient cell number and/or viability for analysis.  494 
 495 
Figure 2. Graph plot depicting interpretations of flow cytometry standard (FCS) files by 496 
immunophenotypic category. Eight investigators interpreted each file. Other: Constellation of 497 
antigen expression equivocal for a neoplastic or reactive process. Uninterpretable: Files that 498 
investigators could not analyze due to software incompatibilities. 499 
